as on February 20, 2026 at 7:59 am IST
Day's Low
Day's High
3.02%
Downside
0.13%
Upside
52 Week's Low
52 Week's High
12.85%
Downside
132.58%
Upside
Check Summit Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$11.7B
EPS (TTM)
-0.8025
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-15.59
Industry PE ratio
5.036261682242991
PEG Ratio
0EBITDA
-935.0M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
-292.49%
Track how Summit Therapeutics Inc P/E has moved over time to understand its valuation trends.
Summit Therapeutics Inc in the last 5 years
Lowest (-72.24x)
March 31, 2025
Today (-15.59x)
February 19, 2026
Industry (5.04x)
February 19, 2026
Highest (-0.61x)
April 30, 2023
Today’s Price to Earnings Ratio: -15.59x
Compare market cap, revenue, PE, and other key metrics of Summit Therapeutics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $11.7B | 116.64% | -15.59 | 0.00% | |
| BUY | $121.2B | 127.18% | 31.14 | 32.94% | |
| NA | $39.3B | NA | 682.42 | 1.38% | |
| BUY | $44.1B | 114.55% | 142.75 | 8.45% | |
| BUY | $83.9B | 68.41% | 19.12 | 31.41% |
The Summit Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Summit Therapeutics Inc investment value today
Current value as on today
₹78,321
Returns
Returns from Summit Therapeutics Inc Stock
Dollar Returns*
₹4,849 (+4.85%)
Based on 7 analysts
85.71%
Buy
14.29%
Hold
0.00%
Sell
Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Summit Therapeutics Inc. Average target price of $32.65
Get share price movements and forecasts by analysts on Summit Therapeutics Inc.
What analysts predicted
51.39%UPSIDE
Target Price
$32.65
Current Price
$15.87
Analyzed by
7 Analysts
Target
$32.65
Summit Therapeutics Inc target price $32.65, a slight upside of 51.39% compared to current price of $15.87. According to 7 analysts rating.
Investment in Summit Therapeutics Inc Shares on INDmoney has dropped by -1.72% over the past 30 days, indicating reduced transactional activity.
Time period: to
Search interest for Summit Therapeutics Inc Stock has decreased by -12% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 09 December
Tue, 09:34 PM
-Concerns rise over Summit's non-oncology growth ahead of Keytruda's exclusivity loss in 2028.
Wed, 03:35 AM
-Summit Therapeutics' ivonescimab shows promise, outperforming Keytruda in lung cancer studies with projected sales of $4.4 billion by 2030.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Best in 3 Years
![]()
In the last 3 years, SMMT has outperformed top 5 stocks with highest market-cap in its industry
Price Rise
![]()
In the last 7 days, SMMT stock has moved up by 8.5%
Against Peers
![]()
In the last 1 year, Beone Medicines Ltd has given 51.7% return, outperforming this stock by 78.2%
Revenue Fall
![]()
Revenue is down for the last 3 quarters, 235.0K → -235.0K (in $), with an average decrease of 100.0% per quarter
Profit Down
![]()
Netprofit is down for the last 5 quarters, -56.25M → -231.79M (in $), with an average decrease of 70.0% per quarter
| Organisation | Summit Therapeutics Inc |
| Headquarters | 601 Brickell Key Drive, Miami, FL, United States, 33131 |
| Industry | Health Technology |
| CEO | Mr. Robert W. Duggan |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Mr. Nathan LiaBraaten | Senior Director of Investor Relations |
Dr. Urte Gayko Ph.D. | Chief Regulatory, Quality & Pharmacovigilance Officer |
Dr. Allen S. Yang M.D., Ph.D. | Head of R&D Strategy |
Mr. Manmeet Singh Soni CPA | COO, CFO & Director |
Prof. Kay Elizabeth Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |
Mr. Bhaskar Anand | Chief Accounting Officer |
Mr. Dave Gancarz | Chief Business & Strategy Officer |
Dr. Fong Clow | Chief Biometrics Officer |
Mr. Robert W. Duggan | Co-CEO & Executive Chairman |
Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-CEO, President & Director |
Summit Therapeutics Inc share price today is $15.87 as on at the close of the market. Summit Therapeutics Inc share today touched a day high of $15.89 and a low of $15.39.
Summit Therapeutics Inc share touched a 52 week high of $36.91 on and a 52 week low of $13.83 on . Summit Therapeutics Inc stock price today i.e. is closed at $15.87,which is 57.00% down from its 52 week high and 14.75% up from its 52 week low.
Summit Therapeutics Inc market capitalisation is $0.01T as on .
Indian investors can start investing in Summit Therapeutics Inc (SMMT) shares with as little as ₹91.108 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹911.08 in Summit Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Summit Therapeutics Inc share’s latest price of $15.87 as on February 20, 2026 at 2:29 am IST, you will get 0.6301 shares of Summit Therapeutics Inc. Learn more about
fractional shares .
Summit Therapeutics Inc stock has given 116.64% share price returns and 25.07% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?